---
title: Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum
date: '2023-10-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37874105/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231024180945&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Substantial cost reduction can be achieved using p217+tau
  alone to select participants with MCI or mild dementia for a clinical trial designed
  to slow cognitive decline over two years, compared to participant selection by PET.
  In pre-clinical AD trials, p217+tau provides significant cost-saving if used as
  a pre-screening measure for PET A+ or T+ but in MCI/mild dementia trials this may
  add to cost both in testing and in the increased number of participants needed for
  ...'
disable_comments: true
---
CONCLUSIONS: Substantial cost reduction can be achieved using p217+tau alone to select participants with MCI or mild dementia for a clinical trial designed to slow cognitive decline over two years, compared to participant selection by PET. In pre-clinical AD trials, p217+tau provides significant cost-saving if used as a pre-screening measure for PET A+ or T+ but in MCI/mild dementia trials this may add to cost both in testing and in the increased number of participants needed for ...